Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs

Journal of Clinical Microbiology

Volumn 51, Issue 1, 2013, Pages 117-124

  Castanheira, Mariana ^a   Woosley, Leah N ^a   Diekema, Daniel J ^b   Jones, Ronald N ^a   Pfaller, Michael A ^a,b  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; INTERNAL TRANSCRIBED SPACER; MICAFUNGIN; POSACONAZOLE; SPACER DNA; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANALYTICAL ERROR; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA FERMENTATI; CANDIDA INTERMEDIA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DEBARYOMYCES FABRYI; DEBARYOMYCES NEPALENSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC ERROR; DISEASE SURVEILLANCE; DNA SEQUENCE; FUNGAL EXAMINATION; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; IN VITRO STUDY; KODOMAEA OHMERI; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MYCOSIS; NONHUMAN; PICHIA ANOMALA; PICHIA FABIANNI; PICHIA GUILLIERMONDII; PRIORITY JOURNAL;

CANDIDA; DIAGNOSTIC ERRORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGICAL TECHNIQUES; MYCOLOGICAL TYPING TECHNIQUES; MYCOLOGY; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

CANDIDA; CANDIDA ALBICANS; CANDIDA FERMENTATI; CANDIDA INTERMEDIA; CANDIDA METAPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DEBARYOMYCES FABRYI; DEBARYOMYCES HANSENII; DEBARYOMYCES NEPALENSIS; PICHIA; PICHIA GUILLIERMONDII;

EID: 84871674048     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01686-12     Document Type: Article

References (44)

1. Barnett JA, Payne RW, Yarrow D. 2000. Yeasts: characteristics and identification, 3rd ed. University Press, Cambridge, United Kingdom.
2. Quiros M, Martorell P, Valderrama MJ, Querol A, Peinado JM, de Siloniz MI. 2006. PCR-RFLP analysis of the IGS region of rDNA: a useful tool for the practical discrimination between species of the genus Debaryomyces. Antonie Van Leeuwenhoek 90:211-219. (Pubitemid 44314599)
3. Ahmed IM, Gupta A, Gould K, Clark SC. 2005. A fatal fungus. Ann. Thorac. Surg. 80:723-724. (Pubitemid 41019519)
4. Carrega G, Riccio G, Santoriello L, Pasqualini M, Pellicci R. 1997. Candida famata fungemia in a surgical patient successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 16:698-699. (Pubitemid 27470348)
5. Desnos-Ollivier M, Ragon M, Robert V, Raoux D, Gantier JC, Dromer F. 2008. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J. Clin. Microbiol. 46:3237-3242.
6. Krcmery V, Kunova A. 2000. Candida famata fungemia in a cancer patient: case report. J. Chemother. 12:189-190. (Pubitemid 30220269)
7. St-Germain G, Laverdiere M. 1986. Torulopsis candida, a new opportunistic pathogen. J. Clin. Microbiol. 24:884-885. (Pubitemid 17169434)
8. Turunc T, Demiroglu YZ, Aliskan H, Colakoglu S, Arslan H. 2009. Retrospective evaluation of the cases with Candida famata fungemia in a burn unit. Mikrobiyol. Bul. 43:71-76.
9. Wagner D, Sander A, Bertz H, Finke J, Kern WV. 2005. Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 33:397-400. (Pubitemid 41552023)
10. Gupta A, Mi H, Wroe C, Jaques B, Talbot D. 2006. Fatal Candida famata peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. Nephrol. Dial. Transplant. 21:2036-2037. (Pubitemid 43985758)
11. Quindos G, Cabrera F, Arilla MC, Burgos A, Ortiz-Vigon R, Canon JL, Ponton J. 1994. Fatal Candida famata peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis who was treated with fluconazole. Clin. Infect. Dis. 18:658-660. (Pubitemid 24106933)
12. Carrasco L, Ramos M, Galisteo R, Pisa D, Fresno M, Gonzalez ME. 2005. Isolation of Candida famata from a patient with acute zonal occult outer retinopathy. J. Clin. Microbiol. 43:635- 640.
13. Rao NA, Nerenberg AV, Forster DJ. 1991. Torulopsis candida (Candida famata) endophthalmitis simulating Propionibacterium acnes syndrome. Arch. Ophthalmol. 109:1718-1721.
14. Wong B, Kiehn TE, Edwards F, Bernard EM, Marcove RC, de Harven E, Armstrong D. 1982. Bone infection caused by Debaryomyces hansenii in a normal host: a case report. J. Clin. Microbiol. 16:545-548. (Pubitemid 12050052)
15. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48: 1366-1377.
16. Jensen RH, Arendrup MC. 2011. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J. Clin. Microbiol. 49:549-556.
17. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. 2012. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program. Mycopathologia 174:259-271.
18. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. 2006. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 44:693-699.
20. Clinical and Laboratory Standards Institute. 2008. MM18-A. Interpretive criteria for identification of bacteria and fungi byDNAtarget sequencing; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Nguyen HV, Gaillardin C, Neuveglise C. 2009. Differentiation of Debaryomyces hansenii and Candida famata by rRNA gene intergenic spacer fingerprinting and reassessment of phylogenetic relationships among D. hansenii, C. famata, D. fabryi, C. flareri (=D. subglobosus) and D. prosopidis: description of D. vietnamensis sp. nov. closely related to D. nepalensis. FEMS Yeast Res. 9:641-662.
22. Marklein G, Josten M, Klanke U, Muller E, Horre R, Maier T, Wenzel T, Kostrzewa M, Bierbaum G, Hoerauf A, Sahl HG. 2009. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J. Clin. Microbiol. 47:2912-2917.
23. van Veen SQ, Claas EC, Kuijper EJ. 2010. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. J. Clin. Microbiol. 48:900-907.
24. Johnson EM. 2009. Rare and emerging Candida species. Curr. Fungal Infect. Rep. 3:152-159.
25. Hata DJ, Hall L, Fothergill AW, Larone DH, Wengenack NL. 2007. Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card. J. Clin. Microbiol. 45:1087-1092. (Pubitemid 46626468)
26. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2009. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J. Clin. Microbiol. 47:242-244.
27. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
28. Pinto A, Halliday C, Zahra M, van Hal S, Olma T, Maszewska K, Iredell JR, Meyer W, Chen SC. 2011. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 6 :e25712. doi:10.1371/journal.pone.0025712.
29. Stevenson LG, Drake SK, Shea YR, Zelazny AM, Murray PR. 2010. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J. Clin. Microbiol. 48:3482-3486.
30. Hendrickx M, Goffinet JS, Swinne D, Detandt M. 2011. Screening of strains of the Candida parapsilosis group of the BCCM/IHEM collection by MALDI-TOF MS. Diagn. Microbiol. Infect. Dis. 70:544-548.
31. Iriart X, Lavergne RA, Fillaux J, Valentin A, Magnaval JF, Berry A, Cassaing S. 2012. Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. J. Clin. Microbiol. 50:2107-2110.
32. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Brown SD, Motyl M, Perlin DS, Espinel-Ingroff A, Alexander BD. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
33. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D, CLSI Subcommitte for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
34. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J. Clin. Microbiol. 49: 630-637.
35. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
36. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J. Clin. Microbiol. 49:3800-3804.
37. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
38. Pfaller MA, Espinel-Ingroff A, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Faller J, Ghannoum M, Jones RN, Lockhart SR, Ostrosky-Zeichner L, Pelaez T. 2012. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J. Clin. Microbiol. 50:2040-2046.
39. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312. (Pubitemid 351915657)
40. Perlin DS. 2011. Echinocandin-resistant Candida: molecular methods and phenotypes. Cum. Fungal Infect. Rep. 5:113-119.
41. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
42. Nishikawa A, Sugita T, Shinoda T. 1997. Differentiation between Debaryomyces hansenii/Candida famata complex and Candida guilliermondii by polymerase chain reaction. FEMS Immunol. Med. Microbiol. 19:125-129. (Pubitemid 27467065)
43. Nishikawa A, Tomomatsu H, Sugita T, Ikeda R, Shinoda T. 1996. Taxonomic position of clinical isolates of Candida famata. J. Med. Vet. Mycol. 34:411-419. (Pubitemid 26420100)
44. Dhiman N, Hall L, Wohlfiel SL, Buckwalter SP, Wengenack NL. 2011. Performance and cost analysis of matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine identification of yeast. J. Clin. Microbiol. 49:1614-1616.